Assessment of time from cytoreductive nephrectomy (CN) to initiation of targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC).
Winston Vuong(City of Hope), Sumanta Kumar Pal(City of Hope), Nora Ruel(City Of Hope National Medical Center), Robert A. Figlin(Palmetto Hematology Oncology), Courtney Carmichael(City of Hope), Joann Hsu(City of Hope), Mark Chang(City of Hope)
Cited by 0
Related Papers
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
|Cancer Immunology Research|2018|136
Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: A retrospective analysis☆
|Urologic Oncology Seminars and Original Investigations|2012|21
Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies
|Clinical Genitourinary Cancer|2015|15
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
|Journal of Clinical Oncology|2024|9
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010
|European Urology Oncology|2024|4